
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Denali Therapeutics Inc (DNLI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: DNLI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $31.5
1 Year Target Price $31.5
15 | Strong Buy |
4 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.13% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.29B USD | Price to earnings Ratio - | 1Y Target Price 31.5 |
Price to earnings Ratio - | 1Y Target Price 31.5 | ||
Volume (30-day avg) 19 | Beta 1.36 | 52 Weeks Range 10.57 - 33.33 | Updated Date 08/28/2025 |
52 Weeks Range 10.57 - 33.33 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.71 | Actual -0.72 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.99% | Return on Equity (TTM) -39.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1428517536 | Price to Sales(TTM) 3643.65 |
Enterprise Value 1428517536 | Price to Sales(TTM) 3643.65 | ||
Enterprise Value to Revenue 2843.16 | Enterprise Value to EBITDA -8.66 | Shares Outstanding 146212000 | Shares Floating 131925876 |
Shares Outstanding 146212000 | Shares Floating 131925876 | ||
Percent Insiders 9.83 | Percent Institutions 96.3 |
Upturn AI SWOT
Denali Therapeutics Inc

Company Overview
History and Background
Denali Therapeutics Inc. was founded in 2015 by scientists and entrepreneurs committed to defeating neurodegenerative diseases. The company focuses on discovering and developing therapies for diseases like Alzheimer's and Parkinson's.
Core Business Areas
- Small Molecule Programs: Denali is developing small molecule therapeutics designed to cross the blood-brain barrier and target specific mechanisms involved in neurodegeneration.
- Antibody Transport Vehicle (ATV) Technology: Denali's ATV technology facilitates the delivery of large molecule therapeutics, like antibodies and enzymes, across the blood-brain barrier to treat CNS diseases.
- Engineered Enzymes: This involves designing and developing recombinant enzymes to address lysosomal dysfunction, a hallmark of many neurodegenerative diseases.
Leadership and Structure
Denali is led by Ryan Watts, Ph.D., CEO, and a team of experienced pharmaceutical executives. The company has a functional organizational structure, with dedicated teams for research, development, and commercialization.
Top Products and Market Share
Key Offerings
- Takeda Collaboration Programs: Denali has a collaboration with Takeda Pharmaceutical for therapies targeting neuroinflammation in neurodegenerative diseases. While specific market share isn't publicly available, the collaboration represents a significant source of funding and potential revenue. Competitors include companies with neuroinflammation programs, such as Biogen (BIIB) and Roche (RHHBY).
- SAR443820 (DNL310): DNL310 is a recombinant enzyme designed to treat Hunter syndrome. It is partnered with Sanofi (SNY). Market share data is not yet available as the product is in clinical trials. Competing approaches are enzyme replacement therapies like Elaprase from Takeda.
- DNL788: DNL788 is a RIPK1 inhibitor being developed for systemic autoimmune diseases. Market share data is not available. Other companies developing RIPK1 inhibitors include GSK.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing, driven by an aging population and the lack of effective treatments. The market is highly competitive and fragmented.
Positioning
Denali Therapeutics is positioned as a leader in developing therapies that can cross the blood-brain barrier, a major challenge in treating CNS diseases. Their ATV technology gives them a competitive advantage.
Total Addressable Market (TAM)
The neurodegenerative disease market is projected to reach hundreds of billions of dollars. Denali is positioned to capture a significant portion of this TAM with its innovative drug delivery technology.
Upturn SWOT Analysis
Strengths
- Novel blood-brain barrier technology (ATV)
- Strong scientific expertise in neurodegeneration
- Strategic partnerships with major pharmaceutical companies
- Deep pipeline of drug candidates
Weaknesses
- High cash burn rate
- Clinical trial risk
- Dependence on partnerships for funding
- Limited commercialization experience
Opportunities
- Expanding the application of ATV technology to new therapeutic areas
- Advancing pipeline candidates through clinical development
- Acquiring complementary technologies or companies
- Securing additional partnerships for drug development and commercialization
Threats
- Clinical trial failures
- Competition from other companies developing CNS therapies
- Regulatory hurdles
- Changes in the reimbursement landscape
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Roche (RHHBY)
- Eli Lilly (LLY)
- AbbVie (ABBV)
Competitive Landscape
Denali's advantage lies in its ATV technology, but it faces competition from larger, more established pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Denali's historical growth has been driven by its pipeline advancement and strategic partnerships. The company has experienced significant growth in its research and development activities.
Future Projections: Future growth is dependent on the successful development and commercialization of its pipeline candidates. Analyst estimates vary, but generally anticipate continued growth in revenue and R&D spending.
Recent Initiatives: Recent initiatives include advancing key pipeline candidates into later-stage clinical trials and expanding partnerships with pharmaceutical companies.
Summary
Denali Therapeutics is a promising biotech company focused on neurodegenerative diseases. Its ATV technology is a key differentiator, but clinical trial success and financial stability are crucial. Collaborations provide needed capital but can dilute future revenue streams. Overcoming clinical risks and securing funding remain pivotal for its continued success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Denali Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share figures are estimates and may not be precise. Financial data should be verified through official company reports.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Denali Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2017-12-08 | Co-Founder, President, CEO & Director Dr. Ryan J. Watts Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 486 | |
Full time employees 486 |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.